Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02735252 · ClinicalTrials.gov registry record · NA
PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
A NA study of Prostate Cancer and Advanced Renal Cell Carcinoma, sponsored by University of California, San Francisco.
- Active
- Registry status
- NA
- Development phase
- 156
- Enrollment target
- 1
- Study location
NCT02735252 is a NA study of Prostate Cancer and Advanced Renal Cell Carcinoma that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 156 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02735252, a NA study of Prostate Cancer and Advanced Renal Cell Carcinoma, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 156 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a tissue and blood collection protocol requiring image-guided biopsies of metastatic prostate cancer and other genitourinary malignancies including renal cell carcinoma and urothelial carcinoma. Whenever possible, a new bone lesion or new/progressing soft tissue lesion will be chosen for biopsy as opposed to radiographically stable lesion. Patients will be enrolled in into one of several parallel cohorts based upon disease status or type and the planned systemic therapy following baseline tumor biopsy: (A) Androgen signaling inhibition, (B) Immunotherapy, (C) Radiotherapy, (D) Targeted Therapy/Investigational therapeutic, (E) DNA damage response pathway, (F) Aggressive variant disease, (G1) Castration-sensitive ADT naïve and ADT \< 3 months), or (G2) Castration-sensitive pre-treated with sub-optimal PSA nadir \>0.2 ng/ml, (R) metastatic renal cell carcinoma and metastatic and (U) urothelial carcinoma.
Conditions Studied
Interventions
- OTHER Systemic therapy
- DEVICE StrataNGS
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2016-05-25 |
| Est. Completion | 2027-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02735252
The ClinicalTrials.gov registry entry for NCT02735252 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (74% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Systemic therapy is the first listed.
NCT02735252 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02735252 about?
NCT02735252 is a clinical study titled "PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer". This is a tissue and blood collection protocol requiring image-guided biopsies of metastatic prostate cancer and other genitourinary malignancies including renal cell carcinoma and urothelial carcinoma. Whenever possible, a new bone lesion or new/progressing soft tissue lesion will be chosen for bio...
What is the current status of trial NCT02735252?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 156 participants. The study started on 2016-05-25. Estimated completion is 2027-03-31.
What conditions does trial NCT02735252 study?
This clinical trial studies the following conditions: Prostate Cancer, Advanced Renal Cell Carcinoma, Genitourinary Cancer, Advanced Urothelial Carcinoma.
What interventions are being tested in trial NCT02735252?
The interventions under investigation include: Systemic therapy (OTHER), StrataNGS (DEVICE).
Who is sponsoring clinical trial NCT02735252?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02735252 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.